Reata Pharmaceuticals Inc (NASDAQ:RETA) CAO Sells $388,480.00 in Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) CAO Elaine Castellanos sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $194.24, for a total value of $388,480.00. Following the completion of the sale, the chief accounting officer now owns 17,146 shares in the company, valued at approximately $3,330,439.04. The transaction was disclosed in a filing with the SEC, which is available at this link.

Elaine Castellanos also recently made the following trade(s):

  • On Monday, October 28th, Elaine Castellanos sold 4,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $200.00, for a total transaction of $800,000.00.
  • On Friday, October 25th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $190.00, for a total transaction of $380,000.00.
  • On Friday, October 18th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $170.00, for a total transaction of $340,000.00.
  • On Monday, October 14th, Elaine Castellanos sold 3,000 shares of Reata Pharmaceuticals stock. The shares were sold at an average price of $105.00, for a total transaction of $315,000.00.
  • On Friday, September 6th, Elaine Castellanos sold 2,000 shares of Reata Pharmaceuticals stock. The stock was sold at an average price of $85.00, for a total transaction of $170,000.00.

Shares of NASDAQ:RETA opened at $204.60 on Friday. Reata Pharmaceuticals Inc has a 1 year low of $47.50 and a 1 year high of $222.33. The firm has a market capitalization of $5.91 billion, a PE ratio of -71.29 and a beta of 2.64. The business’s 50 day moving average price is $198.69 and its 200-day moving average price is $114.31.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.07). The business had revenue of $8.24 million for the quarter, compared to analysts’ expectations of $7.43 million. Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,281.61%. The firm’s revenue was up 59.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.07) EPS. On average, analysts forecast that Reata Pharmaceuticals Inc will post -5.35 earnings per share for the current year.

RETA has been the subject of a number of recent analyst reports. Leerink Swann set a $230.00 price objective on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 15th. BidaskClub raised shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 2nd. Cantor Fitzgerald raised their target price on Reata Pharmaceuticals from $250.00 to $314.00 in a research report on Wednesday, November 27th. ValuEngine downgraded Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Jefferies Financial Group lifted their price target on shares of Reata Pharmaceuticals from $128.00 to $254.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Reata Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $255.63.

A number of institutional investors have recently made changes to their positions in RETA. Amundi Pioneer Asset Management Inc. lifted its holdings in Reata Pharmaceuticals by 37.1% in the second quarter. Amundi Pioneer Asset Management Inc. now owns 183,919 shares of the company’s stock valued at $17,353,000 after acquiring an additional 49,814 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Reata Pharmaceuticals by 6.7% in the 2nd quarter. Farallon Capital Management LLC now owns 800,000 shares of the company’s stock worth $75,480,000 after acquiring an additional 50,000 shares during the last quarter. Dupont Capital Management Corp purchased a new position in shares of Reata Pharmaceuticals during the 3rd quarter worth approximately $283,000. Optimum Investment Advisors purchased a new position in shares of Reata Pharmaceuticals during the 2nd quarter worth approximately $76,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in Reata Pharmaceuticals by 512.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 45,300 shares of the company’s stock valued at $4,147,000 after purchasing an additional 37,900 shares during the last quarter. Hedge funds and other institutional investors own 60.04% of the company’s stock.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Read More: Conference Calls and Individual Investors

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit